Skip to nav Skip to content

Raad Gharaibeh, PhD

Program: Biostatistics and Bioinformatics

ORCID: 0000-0001-5484-8902

  • Overview

    Dr. Gharaibeh main area of interest is translational bioinformatics, with a central focus on cancer microbial genomics. His work aims to understand the functional capacities of the microbiome and their contributions to the cancer continuum, ultimately leveraging this knowledge to develop effective therapeutic and diagnostic strategies.

    Associations

    • Biostatistics and Bioinformatics
  • Research Interest

    My overarching goal is to harness the power of microbiome to develop new and effective therapeutic and diagnostic strategies. My research interest can be divided into three complementary areas: The first area is dedicated to answering the initial question of: “Who is there?” and achieved by comparing microbiota composition in different ecosystems (e.g. human, mouse) between experimental groups (e.g. treatment vs. control) and exposure (diet, antibiotics, lifestyle, etc.) through the analysis of 16S rRNA gene sequences and whole genome metagenome. The second area focuses on answering the question of: “Wha are they doing?” and this is done by examining the functional capacity of the microbiota through the analysis of shotgun metagenome and/or metatranscriptome sequencing. For that, I examine the genes that are present in the microbiota and their expression between experimental groups and cohorts. This adds to the knowledge gained from the first area as now we know both who is there and what they are doing in each experimental group. The third area is devoted to answering the question: “How do they do it?”. This can be answered by computationally deciphering the functional capacities of the microbiota through the identification of enzymes/molecules of interest. While many microbiome studies have focused on the overall difference of gut microbiota between experimental groups, the mechanistic connections between the microbiome and those groups remain poorly investigated and understood. This area serves as a zoom-in approach on the knowledge gained from the first two areas, focusing on specific microbial products that impact treatment, drug efficacy and/or metabolism in the experimental groups under investigation.

  • Publications

    • Oka A, Bongers G, Mishima Y, Baltus AJ, Gray SM, Liu B, Herzog JW, Benedetto JR, Fan TJ, Jang J, Awoniyi M, Rousta E, Hao LY, Gharaibeh RZ, Fodor AA, Ohkusa T, Atarashi K, Fukuda S, Honda K, San Mateo LR, Sartor RB. Defined human Clostridia consortia reverse colitis via dual effects of tryptophan metabolites on microbiota and immunity. Cell Host Microbe. 2026 Sep.34(9):1746-1763.e15. Pubmedid: 42648293. Pmcid: PMC13639900.

Find a Researcher Search